Phase 2 N=38 Spondylitis Trial of Apremilast for Better Rheumatic Therapy
Ankylosing Spondylitis
Primary: Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline — -0.77; -1.59 units on a scale — p=0.139
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition
Trapeziometacarpal Arthrosis
Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years
N/A N=147 Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis · Bone Resorption · Ankylosing Spondylitis
Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2
N/A N=80 Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Ankylosing Spondylitis
Primary: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline — 30.18; 49.09; 53.06; 63.29 Percentage of impairment
Phase 3 N=192 Study of Adalimumab in Patients With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response — 14; 33 participants — p=<0.001
Phase 4 N=82 Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12 — -19.79…
Phase 3 N=1,015 A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
Spondylitis, Ankylosing
Primary: Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen — -31.23; -30.59 mm VAS
Phase 3 N=158 Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Ankylosing Spondylitis · Axial Spondyloarthritis
Primary: Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28 — 65; 18; 40; 33 Participants
Phase 3 N=225 Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 — 32.38; 15.74 Percentage of participants — p=0.0062
N/A N=763 Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel
Spondyloarthrosis
Primary: Percentage of Participants With 7 Years Adherence to Etanercept — 60.6 Percentage of participants
Phase 3 N=356 A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Assessment in Ankylosing Spondylitis 20 Responders at Week 14 — 17; 82; 84; 166 Participants — p=<0.001
Phase 3 N=82 Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12 — 18; 12; 20; 32…
Phase 4 N=90 A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Change From Baseline in Non Steroidal Anti Inflammatory Drug (NSAID) Assessment of the SpondyloArthritis International Society (ASAS) Score at Week 8. — -63.90; -36.63…
Phase 4 N=566 Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
Phase 3 N=165 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
Peripheral Spondyloarthritis
Primary: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12 — 39.3; 19.8; 60.7; 80.2 percentage of participants — p=0.006
Phase 3 N=859 Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Ankylosing Spondylitis
Primary: Percentage of Participants With no Radiographic Progression at Week 104 (Multiple Imputation) (Full Analysis Set) — 66.1; 66.9; 65.6 Percentage of participants — p=0.7164
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
N/A N=55 Exercise Therapy Program in Ankylosing Spondylitis Patients
Ankylosing Spondylitis
Primary: FUNCTIONAL INDEX — 3.4; 4.3; 3.2; 4.5 units on a scale — p=0.13
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
N/A N=89 Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving BASDAI 40 Response at Week 24 — 83.6 Percentage of participants
N/A N=152 Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Ankylosing Spondylitis
Primary: Percentage of Participants With Unchanged First Line Anti-TNF Treatment Up to Month 18 — 85.42 percentage of participants
Phase 3 N=490 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Ankylosing Spondyloarthritis
Primary: Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 — 36.6; 35.0; 32.5 Percentage of…
Phase 4 N=24 Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy
Spondylarthropathies, Enthesitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for Patient Global Assessment of Disease Activity (PGA) Between Randomization and Week 12 — -28.54; -11.07 mm…
Phase 3 N=325 Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Spondyloarthropathies
Primary: Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12 — 38.3; 57.7; 63.6; 60.6 percentage of participants — p==0.004
Phase 3 N=498 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
Axial Psoratic Arthritis
Primary: Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 — 66.3; 62.9; 31.2 percentage of participants…
Phase 3 N=208 A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16…
Phase 4 N=84 Extension Study Evaluating Etanercept in Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Patients Using Healthcare Resources in the 48 Weeks Before and During Treatment — 6; 4; 8; 4 patients — p=0.743
Phase 3 N=773 A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment) — 83.3; 54.7 Percentage of participants — p=<0.001
N/A N=53 Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Fulfillment of Bath Ankylosing Spondylitis Disease Activity Index 50 Response (BASDAI50) — 31 Participants
Phase 3 N=41 A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12 — 30; 30; 30 Subjects